{"id":"https://openalex.org/W4394197829","doi":"https://doi.org/10.6084/m9.figshare.21790196","title":"Supplementary Material for: Adverse Events of Immune Checkpoint Inhibitor-Based Therapies for Unresectable Hepatocellular Carcinoma in Prospective Clinical Trials: A Systematic Review and Meta-analysis","display_name":"Supplementary Material for: Adverse Events of Immune Checkpoint Inhibitor-Based Therapies for Unresectable Hepatocellular Carcinoma in Prospective Clinical Trials: A Systematic Review and Meta-analysis","publication_year":2022,"publication_date":"2022-01-01","ids":{"openalex":"https://openalex.org/W4394197829","doi":"https://doi.org/10.6084/m9.figshare.21790196"},"language":"en","primary_location":{"id":"pmh:oai:figshare.com:article/21790196","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_Adverse_Events_of_Immune_Checkpoint_Inhibitor-Based_Therapies_for_Unresectable_Hepatocellular_Carcinoma_in_Prospective_Clinical_Trials_A_Systematic_Review_and_Meta-analysis/21790196","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"},"volume":null,"type":"supplementary-materials","indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_Adverse_Events_of_Immune_Checkpoint_Inhibitor-Based_Therapies_for_Unresectable_Hepatocellular_Carcinoma_in_Prospective_Clinical_Trials_A_Systematic_Review_and_Meta-analysis/21790196","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Y., Zhang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y., Zhang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"M., Wang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M., Wang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Q., Chen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Q., Chen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005132315","display_name":"Yong\u2010Qiang Deng","orcid":"https://orcid.org/0000-0002-2306-1039","observed_orcids":["https://orcid.org/0000-0002-2306-1039"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y., Deng","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018799831","display_name":"J. Chen","orcid":"https://orcid.org/0009-0007-8898-2377","observed_orcids":["https://orcid.org/0009-0007-8898-2377"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J., Chen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032341066","display_name":"Yong Dai","orcid":"https://orcid.org/0000-0002-6840-9158","observed_orcids":["https://orcid.org/0000-0002-6840-9158"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y., Dai","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"S., Luo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S., Luo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100380886","display_name":"Jia Xu","orcid":"https://orcid.org/0000-0001-8255-5568","observed_orcids":["https://orcid.org/0000-0001-8255-5568","https://orcid.org/0000-0003-1238-1317"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J., Xu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101461477","display_name":"Hui Zhao","orcid":"https://orcid.org/0000-0003-1614-1994","observed_orcids":["https://orcid.org/0000-0003-1614-1994"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H., Zhao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5101695720","display_name":"Jianhua Cai","orcid":"https://orcid.org/0000-0002-9909-3571","observed_orcids":["https://orcid.org/0000-0002-9909-3571"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J., Cai","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8393999934196472,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8393999934196472,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10073","display_name":"Hepatocellular Carcinoma Treatment and Prognosis","score":0.15860000252723694,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.8550000190734863},{"id":"https://openalex.org/keywords/hepatocellular-carcinoma","display_name":"hepatocellular carcinoma","score":0.9160000085830688},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7369999885559082},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.9929999709129333},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.9570000171661377},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.4350000023841858},{"id":"https://openalex.org/keywords/molecularly-targeted-agents","display_name":"molecularly targeted agents","score":0.7139999866485596},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.6700000166893005},{"id":"https://openalex.org/keywords/treatment-related-mortality","display_name":"non-relapse mortality","score":0.7099999785423279},{"id":"https://openalex.org/keywords/immunotherapy-safety","display_name":"immunotherapy safety","score":0.5370000004768372},{"id":"https://openalex.org/keywords/unresectable-liver-cancer","display_name":"unresectable liver cancer","score":0.7839999794960022},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-related-pneumonitis","display_name":"immune-related pneumonitis","score":0.6000000238418579},{"id":"https://openalex.org/keywords/immune-mediated-colitis","display_name":"immune-related colitis","score":0.8709999918937683},{"id":"https://openalex.org/keywords/immune-related-endocrinopathy","display_name":"immune-related endocrinopathy","score":0.6990000009536743},{"id":"https://openalex.org/keywords/immune-related-dermatitis","display_name":"immune-related dermatitis","score":0.6919999718666077},{"id":"https://openalex.org/keywords/immune-related-hepatitis","display_name":"immune-related hepatitis","score":0.5329999923706055},{"id":"https://openalex.org/keywords/immune-related-nephritis","display_name":"immune-related nephritis","score":0.6639999747276306},{"id":"https://openalex.org/keywords/immune-related-encephalitis","display_name":"immune-related encephalitis","score":0.6129999756813049}],"concepts":[{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.7188035845756531},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6955751776695251},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.6862191557884216},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6240237355232239},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5687400102615356},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5676754117012024},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5096943378448486},{"id":"https://openalex.org/C189708586","wikidata":"https://www.wikidata.org/wiki/Q1504425","display_name":"Systematic review","level":3,"score":0.43300557136535645},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.2179892361164093},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.057047039270401},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"pmh:oai:figshare.com:article/21790196","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_Adverse_Events_of_Immune_Checkpoint_Inhibitor-Based_Therapies_for_Unresectable_Hepatocellular_Carcinoma_in_Prospective_Clinical_Trials_A_Systematic_Review_and_Meta-analysis/21790196","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"},{"id":"doi:10.6084/m9.figshare.21790196","doi":"https://doi.org/10.6084/m9.figshare.21790196","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.21790196","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},{"id":"doi:10.6084/m9.figshare.21790196.v1","doi":"https://doi.org/10.6084/m9.figshare.21790196.v1","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.21790196.v1","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"}],"best_oa_location":{"id":"pmh:oai:figshare.com:article/21790196","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_Adverse_Events_of_Immune_Checkpoint_Inhibitor-Based_Therapies_for_Unresectable_Hepatocellular_Carcinoma_in_Prospective_Clinical_Trials_A_Systematic_Review_and_Meta-analysis/21790196","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4313332161","https://openalex.org/W4309244618","https://openalex.org/W4200037072","https://openalex.org/W3080431037","https://openalex.org/W3166460626","https://openalex.org/W4406869445","https://openalex.org/W4410442091","https://openalex.org/W3209037065","https://openalex.org/W4399613008","https://openalex.org/W2990130589"],"abstract_inverted_index":{"Introduction:":[0],"To":[1],"investigate":[2],"the":[3,40,73,100,107,127,154,239,305,318],"incidence":[4,74,90,108,128,292,307,319],"and":[5,39,71,91,95,115,129,136,168,184,208,257,282,304,320],"spectrum":[6,76,321],"of":[7,61,77,93,105,109,131,160,293,308,322],"adverse":[8,79,84,132],"events":[9,80,85],"in":[10,324,333],"unresectable":[11,62,325],"hepatocellular":[12],"carcinoma":[13],"(HCC)":[14],"patients":[15,64,327],"treated":[16,65],"with":[17,66,151,229,233,238,267],"immune":[18],"checkpoint":[19],"inhibitors":[20],"(ICIs)":[21],"or":[22,68,75,82,330],"ICI-based":[23,69,331],"combinations.":[24],"Methods:":[25],"The":[26,89,103,141,157,235,263,290,336],"study":[27,315,340],"protocol":[28],"was":[29,299,311],"prospectively":[30],"registered":[31],"on":[32],"PROSPERO":[33],"(CRD42022319255).":[34],"We":[35,121],"searched":[36],"PubMed,":[37],"EMBASE,":[38],"Cochrane":[41],"Library":[42],"for":[43],"published":[44],"clinical":[45,334,348],"trials":[46],"from":[47,338],"database":[48],"inception":[49],"to":[50,112,125,296,346],"April":[51],"22,":[52],"2022.":[53],"Studies":[54],"that":[55],"included":[56],"at":[57],"least":[58],"one":[59],"group":[60],"HCC":[63,326],"ICIs":[67,190,209,329],"combinations":[70,332],"reported":[72],"treatment-related":[78,116,309],"(trAEs)":[81],"immune-related":[83],"(irAEs)":[86],"were":[87,99,118,138,171,227,243,271],"eligible.":[88],"spectra":[92,130],"all-grade":[94,161,166,236],"grade":[96,163,201,220,264],"\u22653":[97,164,202,221,265],"trAEs":[98,110,231,237,266,294,323],"primary":[101],"outcomes.":[102,120],"profiles":[104],"irAEs,":[106,167],"leading":[111,295],"treatment":[113,297],"discontinuation,":[114],"mortalities":[117,310],"additional":[119],"applied":[122],"random-effects":[123],"models":[124],"pool":[126],"events.":[133],"Subgroup":[134],"analyses":[135],"meta-regression":[137],"performed.":[139],"Results:":[140],"literature":[142],"search":[143],"identified":[144],"2464":[145],"records.":[146],"Twenty":[147],"studies":[148],"(4146":[149],"participants":[150],"HCC)":[152],"met":[153],"eligibility":[155],"criteria.":[156],"pooled":[158,241,269,291],"incidences":[159,242,270],"trAEs,":[162,165],"grade\u22653":[169],"irAEs":[170],"80.1%":[172],"(95%":[173,177,181,186,301],"CI":[174,178,182,187,198,205,217,224,250,255,261,275,280,288,302],"73.8-85.2),":[175],"35.4%":[176],"27.2-44.6),":[179],"31.1%":[180],"21.0-43.5),":[183],"6.6%":[185],"3.6-11.8),":[188],"respectively.":[189],"plus":[191,210],"oral":[192],"targeted":[193,212],"agents":[194,213],"(all-grade":[195,214],"OR=17.07,":[196],"95%":[197,204,216,223,249,254,260,274,279,287],"6.05-48.16,":[199],"P<0.001;":[200],"OR=9.35,":[203],"4.53-19.29,":[206],"P<0.001)":[207],"intravenous":[211],"OR=4.91,":[215],"1.80-13.42,":[218],"P=0.003;":[219],"OR=4.21,":[222],"1.42-12.48,":[225],"P=0.012)":[226],"associated":[228],"increased":[230,285],"compared":[232],"monotherapy.":[234],"highest":[240,268],"reactive":[244],"capillary":[245],"endothelial":[246],"proliferation":[247],"(49.2%,":[248],"26.3-72.3),":[251],"neutropenia":[252,277],"(34.6%,":[253],"17.1-57.5),":[256],"proteinuria":[258],"(32.8%,":[259],"19.8-49.2).":[262],"hypertension":[272],"(11.1%,":[273],"4.0-29.0),":[276],"(10.5%,":[278],"7.0-15.4),":[281],"aspartate":[283],"aminotransferase":[284],"(7.7%,":[286],"6.3-9.4).":[289],"discontinuation":[298],"8.0%":[300],"6.0-10.5),":[303],"overall":[306],"1.1%.":[312],"Conclusions:":[313],"This":[314],"comprehensively":[316],"summarized":[317],"receiving":[328],"trials.":[335],"results":[337],"this":[339],"will":[341],"provide":[342],"a":[343],"useful":[344],"reference":[345],"guide":[347],"practice.":[349]},"counts_by_year":[],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2024-04-08T00:00:00"}